KLRG1 expression identifies short-lived Foxp3+ Treg effector cells with functional plasticity in islets of NOD mice

Autoimmunity. 2017 Sep;50(6):354-362. doi: 10.1080/08916934.2017.1364368. Epub 2017 Aug 29.

Abstract

A progressive waning in Foxp3+ regulatory T (Treg) cell function provokes autoimmunity in the non-obese diabetic (NOD) mouse model of type 1 diabetes (T1D), a cellular defect rescued by prophylactic IL-2 therapy. We showed that most islet-infiltrating Treg cells express inducible T-cell co-stimulator (ICOS) in pre-diabetic NOD mice, and that ICOS+ Treg cells display enhanced fitness and suppressive function in situ. Moreover, T1D progression is associated with decreased expansion and suppressive activity of ICOS+Foxp3+ Treg cells, in islets, an observation consistent with the exacerbated T1D seen in NOD.BDC2.5 mice in which the ICOS pathway is abrogated. Here, we show that a large proportion of islet-resident Treg cells express the KLRG1 marker of terminally differentiation, in contrast to islet-infiltrating ICOS- Treg or Teff cells. We hypothesized that KLRG1 expression designates a subpopulation of ICOS+ Treg cells in islets that progressively loses function, and contributes to the immune dysregulation observed at T1D onset. Indeed, KLRG1-expressing ICOS+ Treg cells are prone to apoptosis, and have an impaired proliferative capacity and suppressive function in vitro and in vivo. T1D protective low-dose IL-2 treatment in vivo could not rescue the loss of KLRG1-expressing Treg cells in situ. While the global pool of Foxp3+ Treg cells displays some degree of functional plasticity in vivo, the KLRG1+ ICOS+ Treg cell subset is particularly susceptible to lose Foxp3 expression and reprogram into Th1- or Th17-like effector T (Teff) cells in the pancreas microenvironment. Overall, KLRG1 expression delineates a subpopulation of dysfunctional Treg cells during T1D progression in autoantigen-specific TCR transgenic NOD mice.

Keywords: Foxp3+ Treg cells; ICOS; fatigued T cells; type 1 diabetes.

MeSH terms

  • Animals
  • Apoptosis / genetics
  • Apoptosis / immunology
  • Autoimmunity / drug effects
  • Autoimmunity / genetics
  • Cell Proliferation
  • Diabetes Mellitus, Experimental / drug therapy
  • Diabetes Mellitus, Experimental / genetics*
  • Diabetes Mellitus, Experimental / immunology
  • Diabetes Mellitus, Experimental / pathology
  • Diabetes Mellitus, Type 1 / drug therapy
  • Diabetes Mellitus, Type 1 / genetics
  • Diabetes Mellitus, Type 1 / immunology
  • Diabetes Mellitus, Type 1 / pathology
  • Disease Progression
  • Forkhead Transcription Factors / genetics*
  • Forkhead Transcription Factors / immunology
  • Gene Expression Regulation
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Inducible T-Cell Co-Stimulator Protein / genetics
  • Inducible T-Cell Co-Stimulator Protein / immunology
  • Interleukin-2 / pharmacology
  • Islets of Langerhans / drug effects
  • Islets of Langerhans / immunology*
  • Islets of Langerhans / pathology
  • Lectins, C-Type
  • Mice
  • Mice, Inbred NOD
  • Receptors, Immunologic / genetics*
  • Receptors, Immunologic / immunology
  • Signal Transduction
  • T-Lymphocytes, Regulatory / drug effects
  • T-Lymphocytes, Regulatory / immunology*
  • T-Lymphocytes, Regulatory / pathology

Substances

  • Forkhead Transcription Factors
  • Foxp3 protein, mouse
  • Hypoglycemic Agents
  • Icos protein, mouse
  • Inducible T-Cell Co-Stimulator Protein
  • Interleukin-2
  • Klrg1 protein, mouse
  • Lectins, C-Type
  • Receptors, Immunologic